Longitudinal Evaluation of Cytopenias in the Renal Transplant Population
Background. Cytopenias, a common complication for immunosuppressed patients, are known to be associated with adverse transplant outcomes. However, there is little information on cytopenias in recipients treated with the costimulation blockade agent, belatacept. Methods. We compared cytopenia inciden...
Main Authors: | Aileen C. Johnson, MD, Geeta Karadkhele, MS, Wairimu Magua, PhD, MS, Payas Vasanth, MD, Christian P. Larsen, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2022-06-01
|
Series: | Transplantation Direct |
Online Access: | http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001339 |
Similar Items
-
Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
by: Aileen C. Johnson, MD, et al.
Published: (2023-03-01) -
Acquired erythropoietic uroporphyria associated with clonal cytopenia of undetermined significance
by: Leah A. Swanson, MD, et al.
Published: (2023-02-01) -
Post-transplant lymphoproliferative disorder risk and outcomes in renal transplant patients treated with belatacept immunosuppression
by: Jean L. Koff, et al.
Published: (2024-01-01) -
Liver Enzymes and the Development of Posttransplantation Diabetes Mellitus in Renal Transplant Recipients
by: Gerald Klaassen, MSc, et al.
Published: (2017-09-01) -
Plasma Proenkephalin and Poor Long-Term Outcome in Renal Transplant Recipients
by: Lyanne M. Kieneker, MSc, et al.
Published: (2017-08-01)